Franchi Jean M. 4

What Happened

• Jean M. Franchi, Chief Financial Officer of Disc Medicine (IRON), sold a total of 11,156 shares in open-market transactions on Feb 17–18, 2026, generating roughly $719,728 in proceeds. The individual transactions were: 4,075 shares at $62.86 on 2026-02-17 ($256,155); 3,397 shares at a weighted average price of $65.01 on 2026-02-18 ($220,838); and 3,684 shares at a weighted average price of $65.89 on 2026-02-18 (~$242,735). These were sales (not purchases), which for insiders are often routine.

Key Details

• Transaction dates and prices:
  • 2026-02-17: 4,075 shares @ $62.86 = $256,155 (sale)
  • 2026-02-18: 3,397 shares @ weighted avg $65.01 = $220,838 (sale; prices ranged $64.47–$65.45)
  • 2026-02-18: 3,684 shares @ weighted avg $65.89 = $242,735 (sale; prices ranged $65.51–$66.38)
• Total shares sold: 11,156; total proceeds: approx. $719,728.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Notable footnotes:
  • One sale (Feb 17) was a "sell-to-cover" to satisfy tax withholding on vested restricted stock units (not a discretionary sale).
  • The Feb 18 sales were effected under a Rule 10b5-1 trading plan adopted Sept 25, 2025.
  • The Feb 18 prices reported are weighted averages; the filing notes the per-trade price ranges and offers to provide per-price breakdowns on request.
• Filing timeliness: Report filed Feb 19, 2026 — generally within Form 4’s required filing window for these Feb 17–18 transactions (no late-filing indication in provided data).

Context

• These transactions are sales, including a tax-withholding sale tied to RSU vesting and trades under a pre-established 10b5-1 plan. Such sales are commonly routine and do not by themselves indicate management sentiment about the company’s prospects.